Executive summary

A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation. This report analyzed the results of the first 75 patients, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29).

With the median follow-up was 36 months, the study reported low AE rates in both study arms, and early temporary differences in genitourinary scores disappeared over time. The study also found no differences in the EPIC domains of bowel symptoms, sexual symptoms, or bowel ≥G2 toxicities.

Key content topics
Top cancer treatments